下载PDF
{"title":"Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.","authors":"Brent L Wood","doi":"10.1002/cpcy.73","DOIUrl":null,"url":null,"abstract":"<p><p>The identification of residual leukemia following therapy, termed minimal or measurable residual disease (MRD), has emerged as one of the most important prognostic factors for patients with acute leukemia, including acute myeloid leukemia (AML). Flow cytometry is a preferred method for MRD detection due to its general applicability and the rapid results that it makes available. In this article, the basic protocol outlines a simple and efficient method for the labeling of hematopoietic cells from bone marrow or peripheral blood with a panel of monoclonal antibodies designed both to highlight patterns of normal maturation and allow identification of neoplastic hematopoietic progenitor populations with a high degree of sensitivity and specificity. The method was developed in a clinical laboratory setting for the diagnosis of myeloid stem cell disorders and neoplasms, and has been extensively validated both technically and clinically for the detection of MRD in AML. © 2020 The Authors. Basic Protocol: Staining and flow cytometry for AML minimal residual disease detection Support Protocol: Analysis and interpretation of data for AML minimal residual disease detection.</p>","PeriodicalId":11020,"journal":{"name":"Current Protocols in Cytometry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpcy.73","citationCount":"40","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Cytometry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpcy.73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 40
引用
批量引用
Abstract
The identification of residual leukemia following therapy, termed minimal or measurable residual disease (MRD), has emerged as one of the most important prognostic factors for patients with acute leukemia, including acute myeloid leukemia (AML). Flow cytometry is a preferred method for MRD detection due to its general applicability and the rapid results that it makes available. In this article, the basic protocol outlines a simple and efficient method for the labeling of hematopoietic cells from bone marrow or peripheral blood with a panel of monoclonal antibodies designed both to highlight patterns of normal maturation and allow identification of neoplastic hematopoietic progenitor populations with a high degree of sensitivity and specificity. The method was developed in a clinical laboratory setting for the diagnosis of myeloid stem cell disorders and neoplasms, and has been extensively validated both technically and clinically for the detection of MRD in AML. © 2020 The Authors. Basic Protocol: Staining and flow cytometry for AML minimal residual disease detection Support Protocol: Analysis and interpretation of data for AML minimal residual disease detection.
急性髓系白血病微小残留病检测:与正常方法的区别。
治疗后残留白血病的识别,称为微小或可测量的残留病(MRD),已成为急性白血病(包括急性髓系白血病(AML))患者最重要的预后因素之一。流式细胞术是mri检测的首选方法,因为它具有普遍的适用性和快速的结果。在本文中,基本方案概述了一种简单而有效的方法,用于标记来自骨髓或外周血的造血细胞,使用一组单克隆抗体来突出正常成熟的模式,并允许以高度的敏感性和特异性识别肿瘤造血祖细胞群。该方法是在临床实验室环境中开发的,用于髓系干细胞疾病和肿瘤的诊断,并已在技术和临床上广泛验证了AML中MRD的检测。©2020作者。基本方案:AML微小残留疾病检测的染色和流式细胞术支持方案:AML微小残留疾病检测数据的分析和解释。
本文章由计算机程序翻译,如有差异,请以英文原文为准。